Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.
Herbrecht R, et al.
N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191.
N Engl J Med. 2002.
PMID: 12167683
Free article.
Clinical Trial.
BACKGROUND: Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis. ...Voriconazole-treated patients had s …
BACKGROUND: Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to …